fig2
![The immune regulation of PD-1/PDL-1 axis, a potential biomarker in multiple sclerosis](https://image.oaes.cc/cad7e78e-6028-4c92-9620-1812046bbad9/3574.fig.2.jpg)
Figure 2. Immune checkpoints inhibitor treatment induces reactivation of multiple Sclerosis. PD-1 has been described on autoreactive T cells and TFH cells in multiple sclerosis. The link of PD-1 with the ligand PDL-1 controls T cell activation mantaining tollerance (Healthy). The blocking of PD-1 breaks the tollerance by reactivation of antigen-specific cells and causing damage of the target-cells with persistent inflammation in the CNS (Multiple Sclerosis). Contrary, depletion of PD-1+ T cells eliminates activated antigen-specific cells reducing the T cell infiltrates and inflammation in the target-organ (PD-1 blocking). TFH: T Follicular helper cells